$AMPH News

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Piper Sandler Reiterates Neutral on Amphastar Pharma, Lowers Price Target to $21

Needham Downgrades Amphastar Pharma to Hold

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Amphastar Pharmaceuticals (NASDAQ:AMPH) Q1 Results Miss Estimates, Stock Slides After Hours

Amphastar Pharma Q1 Adj. EPS $0.42 Misses $0.70 Estimate, Sales $171.171M Miss $173.392M Estimate

Jefferies Downgrades Amphastar Pharma to Hold, Lowers Price Target to $22

Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $23

Amphastar Pharmaceuticals Authorizes $50M Increase To Its Share Buyback Program-8k

Amphastar Pharmaceuticals Authorizes $50M Increase To Its Share Buyback Program-8k

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference - Slideshow

Amphastar Nanjing Signs 5-Year Supply Agreement With Nanjing Letop Biotechnology For Chemical Intermediates With Payments In Chinese Yuan

Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label

Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $30

Amphastar Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results. Also, Needham maintained a Buy rating on the stock but lowered its price target from $34 to $30.